An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.

Trial Profile

An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZACTIMA 58; ZETA
  • Sponsors AstraZeneca; Sanofi Genzyme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2017.
    • 26 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top